MedTech & Diagnostics

Anika Therapeutics Executive Compensation (FY25)

Name: Anika Therapeutics (ANIK) executive compensation
Creator: Velarion
License: https://intel.velarion.ai/terms

ANIK · Executive and director compensation, fiscal 2022 to 2025

Chief executive, fiscal 2025

◇

Stephen Griffin

Latest say-on-pay support

June 18, 2026

Chief executive pay ratio

◇

To the median employee

Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.

See every company’s exec pay — free for 3 days, no card See the plan and pricing

The paid brief on Anika Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $500 for the board report; $900 for both.

Get the executive brief Get the board briefNo account needed.

Data as of November 5, 2026Latest filing (8-K): June 23, 2026

16 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Anika Therapeutics brief$500Get the executive brief

Velarion Intel, one year, every company

232 figures on this page: 217 cited to the filing that reported them, 15 calculated from figures it prints. See the citations

Frequently asked questions

Answers drawn from the data on this page.

Who is Anika Therapeutics' chief executive and what were they paid?

Stephen Griffin, President and Chief Executive Officer; Former EVP, Chief Financial Officer and Chief Operating Officer, received $2,033,370 in total compensation for fiscal 2025. Griffin's total moved 23.2% lower from the $2,646,150 reported for fiscal 2024.

What was Anika Therapeutics' say-on-pay result?

For fiscal 2025, shareholders backed the say-on-pay proposal with 88.3% of votes cast for or against in favor at the meeting held June 18, 2026.

Which companies are in Anika Therapeutics' peer group?

Companies named in the disclosed peer group include Akebia Therapeutics, Inc., Artivion, Inc., Avid Bioservices, Inc., AxoGen, Inc. and Bioventus Inc., among others.

What is Anika Therapeutics' chief executive pay ratio?

For fiscal 2025, the company reported a chief executive pay ratio of 44:1, against median employee compensation of $112,114.

Executive compensation

Every element reported for each named executive officer, by fiscal year.

Fiscal 2022

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Cheryl Blanchard President and Chief Executive Officer	◇	◇	◇	◇	—	—	◇	◇
Michael Levitz Former EVP, Chief Financial Officer and Treasurer	◇	◇	◇	◇	—	—	◇	◇
David Colleran EVP, General Counsel and Secretary	◇	◇	◇	◇	—	—	◇	◇

Fiscal 2023

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Cheryl Blanchard President and Chief Executive Officer	◇	◇	◇	◇	—	—	◇	◇
Michael Levitz Former EVP, Chief Financial Officer and Treasurer	◇	◇	◇	◇	—	—	◇	◇
David Colleran EVP, General Counsel and Secretary	◇	◇	◇	◇	—	—	◇	◇
Anne Nunes SVP, Chief Operations Officer	◇	◇	◇	◇	—	—	◇	◇

Fiscal 2024

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Cheryl Blanchard President and Chief Executive Officer	◇	◇	◇	◇	—	—	◇	◇
Stephen Griffin EVP, Chief Financial Officer and Treasurer	◇	◇	◇	◇	—	—	◇	◇
Michael Levitz Former EVP, Chief Financial Officer and Treasurer Departed during or after this year	◇	◇	◇	◇	—	—	◇	◇
David Colleran EVP, General Counsel and Secretary	◇	◇	◇	◇	—	—	◇	◇
Anne Nunes SVP, Chief Operations Officer	◇	◇	◇	◇	—	—	◇	◇

Fiscal 2025

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Cheryl Blanchard Executive Chair; Former President and Chief Executive Officer Departed during or after this year	◇	◇	◇	—	—	—	◇	◇
Stephen Griffin President and Chief Executive Officer; Former EVP, Chief Financial Officer and Chief Operating Officer	◇	◇	◇	—	—	—	◇	◇
David Colleran Executive Vice President, General Counsel and Secretary	◇	◇	◇	—	—	—	◇	◇
Anne Nunes Former Senior Vice President, Chief Operations Officer Departed during or after this year	◇	—	◇	—	—	—	◇	— not reconciled
Ian McLeod Senior Vice President, Chief Accounting Officer and Treasurer	◇	◇	◇	—	—	—	◇	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.

Fiscal 2025

Officer	Award	Grant date	Threshold units	Target units	Units granted	Maximum units	Exercise price	Grant date fair value
Anne M. Nunes	RSU	◇	—	—	◇	—	—	◇
Cheryl R. Blanchard	RSU	◇	—	—	◇	—	—	◇
David B. Colleran	RSU	◇	—	—	◇	—	—	◇
Ian W. McLeod	RSU	◇	—	—	◇	—	—	◇
Stephen D. Griffin	RSU	◇	—	—	◇	—	—	◇

Fiscal 2023, 2024 are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.

As disclosed at fiscal 2025 year end

Officer	Award	Unvested units	Market value of unvested units	Exercise price	Expires
Cheryl Blanchard	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	=	—	—
Stephen Griffin	RSU	◇	◇	—	—
	RSU	◇	=	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
David Colleran	RSU	◇	◇	—	—
	RSU	◇	=	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
Ian McLeod	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	=	—	—
	RSU	◇	◇	—	—

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.

Anne Nunes

Former Senior Vice President, Chief Operations Officer · Retention agreement

Severance multiple	◇
Severance base	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇

David Colleran

Executive Vice President, General Counsel and Secretary · Retention agreement

Severance multiple	◇
Severance base	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇

Ian McLeod

Senior Vice President, Chief Accounting Officer and Treasurer · Terms as described in the company’s compensation discussion

Severance cash amount

◇

Director compensation

What each non-employee director was paid.

Fiscal 2025

Director	Fees earned in cash	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
John B. Henneman, III Lead independent director	◇	◇	—	—	—	—	◇
Susan L. N. Vogt	◇	◇	—	—	—	—	◇
Stephen O. Richard	◇	◇	—	—	—	—	◇
William R. Jellison	◇	◇	—	—	—	—	◇
Sheryl L. Conley	◇	◇	—	—	—	—	◇
Joseph H. Capper	◇	◇	—	—	—	—	◇
Gary P. Fischetti	◇	◇	—	—	—	—	◇
Glenn R. Larsen, Ph.D	◇	◇	—	—	—	—	◇

Cheryl R. Blanchard, Ph.D and Stephen D. Griffin served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.

Earlier years are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.

Board cash retainer	◇
Board equity retainer	◇
Total board retainer	◇
Board chair premium	◇
Audit committee chair	◇
Audit committee member	◇
Compensation committee chair	◇
Compensation committee member	◇
Nominating and governance chair	◇
Nominating and governance member	◇

Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Fiscal 2025

Akebia Therapeutics, Inc. AKBA
Artivion, Inc. AORT
Avid Bioservices, Inc. CDMO
AxoGen, Inc. AXGN
Bioventus Inc. BVS
Collegium Pharmaceutical, Inc. COLL
Heron Therapeutics, Inc. HRTX
Karyopharm Therapeutics, Inc. KPTI
MacroGenics, Inc. MGNX
MiMedx Group, Inc. MDXG
Organogenesis Holdings Inc. ORGO
Rigel Pharmaceuticals, Inc. RIGL
SurModics, Inc. SRDX
Travere Therapeutics, Inc. TVTX
Vanda Pharmaceuticals, Inc. VNDA
Vericel Corporation VCEL

Say-on-pay history

Shareholder support for the compensation program, by year.

Year	Meeting	Support	Votes for	Votes against	Abstentions
2025	June 18, 2026	=	◇	◇	◇
2024	June 20, 2025	=	◇	◇	◇
2023	July 9, 2024	=	◇	◇	◇
2022	June 14, 2023	=	◇	◇	◇
2021	June 8, 2022	=	◇	◇	◇
2020	June 16, 2021	=	◇	◇	◇
2019	June 16, 2020	=	◇	◇	◇
2018	June 18, 2019	=	◇	◇	◇
2017	May 31, 2018	=	◇	◇	◇
2016	June 13, 2017	=	◇	◇	◇
2015	June 1, 2016	=	◇	◇	◇

Chief executive pay ratio

As calculated and reported by the company.

Ratio

◇

Median employee compensation

◇

Chief executive total compensation

◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”

- Stephen Griffin (President and Chief Executive Officer; Former EVP, Chief Financial Officer and Chief Operating Officer), FY2025 total compensation $2,033,370 (base salary $500,000) [exec_comp, SEC accession 0001140361-26-017488, filed 2026-04-28]

See a complete sample report

What this page does not include

Everything above is a fact Anika Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.

Peer benchmarking

Where Anika Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.

Executive Compensation Report — $500

Written compensation analysis

A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.

Executive Compensation Report — $500

Board and governance analysis

Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.

Board Governance Report — $500

Realizable pay

What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.

Velarion Intelligence

Adviser switching and vote outcomes

Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.

Inquire about access

Multiple companies at once

Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.

Velarion Intelligence

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.

232 figures on this page: 217 cited to the filing that reported them, 15 calculated from figures it prints.

217 cited to the filing

15 calculated from the filing

Documents cited

8-K, filed June 23, 2026
0001171843-26-004253
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed April 28, 2026
0001140361-26-017488
CEO Pay Ratio · Compensation Discussion and Analysis · Director Compensation · Grants of Plan-Based Awards in 2025 · and 2 more sections
8-K, filed June 24, 2025
0001171843-25-004062
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed April 28, 2025
0001140361-25-016082
Summary Compensation Table
EX-10, filed March 17, 2025
0001171843-25-001486
Exhibit
8-K, filed July 11, 2024
0001171843-24-003900
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed June 11, 2024
0001193125-24-159219
Summary Compensation Table
EX-10, filed March 15, 2024
0001171843-24-001380
Exhibit
8-K, filed June 21, 2023
0001171843-23-004058
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 10, 2022
0001171843-22-004296
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 22, 2021
0001171843-21-004469
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 18, 2020
0001171843-20-004425
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 20, 2019
0001171843-19-004087
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 6, 2018
0001171843-18-004486
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 19, 2017
0001171843-17-003690
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 6, 2016
0001171843-16-010498

Cite this data

This page is free to cite. Attribution we ask for:

Velarion, “Anika Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ANIK (accessed 2026).

Short form: data: Velarion

The paid brief for Anika Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $500 for the board report; $900 for both.

Get the executive brief Get the board briefNo account needed.

16 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Embed this data

A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.

The headline figures, each with its citation.

<iframe src="https://intel.velarion.ai/comp/ANIK/embed" width="560" height="480" style="border:1px solid #d8dee8;border-radius:10px" loading="lazy" title="Anika Therapeutics executive compensation, from Velarion"></iframe>

Connect an AI assistant

Ask your own assistant about Anika Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

{
  "mcpServers": {
    "velarion": {
      "type": "http",
      "url": "https://api.velarion.ai/mcp"
    }
  }
}

Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & Diagnostics CEO pay ratio — MedTech & Diagnostics Say-on-pay support — MedTech & Diagnostics

Peers Anika Therapeutics discloses

The companies named in ANIK's own disclosed peer group.

Akebia Therapeutics, Inc.Artivion, Inc.Avid Bioservices, Inc.AxoGen, Inc.Bioventus Inc.Collegium Pharmaceutical, Inc.Heron Therapeutics, Inc.Karyopharm Therapeutics, Inc.MacroGenics, Inc.MiMedx Group, Inc.Organogenesis Holdings Inc.Rigel Pharmaceuticals, Inc.SurModics, Inc.Travere Therapeutics, Inc.Vanda Pharmaceuticals, Inc.Vericel Corporation

Terms on this page

Say-on-Pay Vote CEO Pay Ratio Median Employee Compensation All companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data

APA

Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854

BibTeX

@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}

More on Anika Therapeutics

Frequently asked questions

Executive compensation

Equity awards granted

Outstanding awards

Severance and change in control

Director compensation

Director fee schedule

Disclosed peer group

Say-on-pay history

Chief executive pay ratio

What this page does not include

Citations

Documents cited

The paid brief for Anika Therapeutics

MedTech & Diagnostics rankings

Peers Anika Therapeutics discloses

Terms on this page